Fedratinib's immune mechanism is thought to inhibit the phosphorylation of STAT3 and STAT5, which could correlate with a STAT3 LOF gene mutation, challenging the idea that endemic mycoses are associated with STAT3 LOF mutations (28). The gene discussed is STAT3; the disease is opportunistic mycosis.